All In Biotech

Drug Trial Radar · NCT05259033

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Semaglutide, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With a GLP 1 Receptor Agonist. COMBINE 2

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 683 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

683

Actual

Start

Apr 11, 2022

Primary completion

Dec 13, 2023

Study completion Jan 16, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries. Participants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls. At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • IcoSemaDrug

    IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen. For about 1 year and 1 month.

  • Semaglutide 1 mgDrug

    Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Haemoglobin (HbA1c)Time frame: Baseline (week 0), (week 52)

Locations

193 sites in 15 countries. Site status is shown where the registry gives one.

  • Univ of AL at Birmingham_BRM

    Birmingham, Alabama

  • Pri Med Grp dba/Gil Ctr Fam

    Gilbert, Arizona

  • Phoenician Centers for Research & Innovation PCRI

    Phoenix, Arizona

  • Clinical Research Institute of Arizona

    Sun City West, Arizona

  • John Muir Physicians Network

    Concord, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • Downtown LA Res Ctr. Inc.

    Los Angeles, California

  • Velocity Clin Res Los Angeles

    Los Angeles, California

  • Velocity Clin Res Wstlke

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • San Diego Family Care_San Diego

    San Diego, California

  • Premier Medical Center, Inc.

    Toluca Lake, California

  • Northeast Research Institute

    Fleming Island, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Northeast Res Inst. Inc.

    Jacksonville, Florida

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Adult Medicine of Lake County, Inc.

    Mt. Dora, Florida

  • Clinical Neuroscience Solution

    Orlando, Florida

  • Florida Institute For Clinical Research

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Javara/Privia Med Grp GA,LLC

    Albany, Georgia

  • Endo Res Solutions Inc

    Roswell, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Saltzer Medical Group Research

    Nampa, Idaho

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Macoupin Research Group

    Gillespie, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Central Illinois Diabetes and Clinical Research

    Springfield, Illinois

  • Velocity Clin. Res Valparaiso

    Valparaiso, Indiana

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Cotton-O'Neil Diab & Endo Ctr

    Topeka, Kansas

  • L-MARC Research Center

    Louisville, Kentucky

  • Four Rivers Clinical Research Inc

    Paducah, Kentucky

  • Ileana J Tandron APMC

    Slidell, Louisiana

  • MedStar Hlth Res Institute

    Hyattsville, Maryland

  • ActivMed Practice & Research LLC

    Methuen, Massachusetts

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.